1
|
Gulacsi L, Pentek M, Rencz F, Brodszky V, Baji P, Vegh Z, Gecse KB, Danese S, Peyrin-Biroulet L, Lakatos PL. Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. Curr Med Chem 2019; 26:259-269. [PMID: 28393687 DOI: 10.2174/0929867324666170406112304] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2016] [Revised: 02/18/2017] [Accepted: 03/01/2017] [Indexed: 12/14/2022]
Abstract
Biological drugs revolutionized the treatment of inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis. However, not all clinically eligible patients have access to biologicals due to significant costs and budget impact. Biosimilars are highly comparable to their originator product in terms of clinical efficacy and safety. Biosimilars are priced 15-75% lower than their reference product, which makes them a less costly alternative and is expected to offer better patients access to biologicals. The total projected cost savings are significant. If the achieved budget savings were used to cover more biological therapy, several additional IBD patients could be treated. Currently, the main barriers to the increasing uptake of biosimilars are the few incentives of the key stakeholders, while physicians' and patients' skepticism towards biosimilars seems to be changing. Over the coming years, biosimilars are expected to gain a growing importance in the treatment of IBD, contributing to a better access to treatment, improving population-level health gain and sustainability of health systems. This review summarizes the results of the literature on the economic considerations of biosimilars in IBD and the role of biosimilar infliximab in the treatment of IBD.
Collapse
Affiliation(s)
- Laszlo Gulacsi
- Department of Health Economics, Corvinus University of Budapest, Fovam ter 8., H-1093 Budapest, Hungary
| | - Marta Pentek
- Department of Health Economics, Corvinus University of Budapest, Fovam ter 8., H-1093 Budapest, Hungary
| | - Fanni Rencz
- Department of Health Economics, Corvinus University of Budapest, Fovam ter 8., H-1093 Budapest, Hungary
| | - Valentin Brodszky
- Department of Health Economics, Corvinus University of Budapest, Fovam ter 8., H-1093 Budapest, Hungary
| | - Petra Baji
- Department of Health Economics, Corvinus University of Budapest, Fovam ter 8., H-1093 Budapest, Hungary.,CERGE-EI Fellow, Semmelweis University, Korányi S. 2/A, H-1083 Budapest, Hungary
| | - Zsuzsanna Vegh
- First Department of Medicine, Semmelweis University, Koranyi S. 2/A, H-1083 Budapest, Hungary
| | - Krisztina B Gecse
- First Department of Medicine, Semmelweis University, Koranyi S. 2/A, H-1083 Budapest, Hungary
| | - Silvio Danese
- IBD Center, Division of Gastroenterology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - Laurent Peyrin-Biroulet
- Department of Hepato-Gastroenterology, University Hospital of Nancy, Allee du Morvan, 54511 Vandoeuvre-l`s-Nancy, France
| | - Peter L Lakatos
- First Department of Medicine, Semmelweis University, Koranyi S. 2/A, H-1083 Budapest, Hungary
| |
Collapse
|
2
|
Simoens S, Jacobs I, Popovian R, Isakov L, Shane LG. Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis. PHARMACOECONOMICS 2017; 35:1047-1062. [PMID: 28660473 PMCID: PMC5606961 DOI: 10.1007/s40273-017-0529-x] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/17/2023]
Abstract
Biosimilar drugs are highly similar to an originator (reference) biologic, with no clinically meaningful differences in terms of safety or efficacy. As biosimilars offer the potential for lower acquisition costs versus the originator biologic, evaluating the economic implications of the introduction of biosimilars is of interest. Budget impact analysis (BIA) is a commonly used methodology. This review of published BIAs of biosimilar fusion proteins and/or monoclonal antibodies identified 12 unique publications (three full papers and nine congress posters). When evaluated alongside professional guidance on conducting BIA, the majority of BIAs identified were generally in line with international recommendations. However, a lack of peer-reviewed journal articles and considerable shortcomings in the publications were identified. Deficiencies included a limited range of cost parameters, a reliance on assumptions for parameters such as uptake and drug pricing, a lack of expert validation, and a limited range of sensitivity analyses that were based on arbitrary ranges. The rationale for the methods employed, limitations of the BIA approach, and instructions for local adaptation often were inadequately discussed. To understand fully the potential economic impact and value of biosimilars, the impact of biosimilar supply, manufacturer-provided supporting services, and price competition should be included in BIAs. Alternative approaches, such as cost minimization, which requires evidence demonstrating similarity to the originator biologic, and those that integrate a range of economic assessment methods, are needed to assess the value of biosimilars.
Collapse
Affiliation(s)
- Steven Simoens
- Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium
| | - Ira Jacobs
- Global Medical Affairs, Pfizer Inc., 235 East 42nd Street, New York, NY, 10017-5755, USA.
| | | | | | - Lesley G Shane
- Outcomes and Evidence, Global Health and Value, Pfizer Inc., New York, NY, USA
| |
Collapse
|
3
|
Affiliation(s)
- François Bocquet
- a Faculty of Pharmacy , Paris Descartes University, Sorbonne Paris Cité , Paris , France
- b Health Law Institute, Inserm, UMR S 1145, Paris Descartes University, Sorbonne Paris Cité , Paris , France
- c General Agency of Equipment and Health Products (AGEPS) , Assistance Publique-Hôpitaux de Paris (AP-HP) , Paris , France
| | - Pascal Paubel
- a Faculty of Pharmacy , Paris Descartes University, Sorbonne Paris Cité , Paris , France
- b Health Law Institute, Inserm, UMR S 1145, Paris Descartes University, Sorbonne Paris Cité , Paris , France
- c General Agency of Equipment and Health Products (AGEPS) , Assistance Publique-Hôpitaux de Paris (AP-HP) , Paris , France
| |
Collapse
|